109012-23-9

Basic information

• Product Name: Ethyl 1-methyl-4-nitroimidazole-2-carboxylate
• Synonyms: ethyl 1-Methyl-4-nitro-1H-iMidazole-2-carboxylate;1-Methyl-4-nitroiMidazole-2-carboxylic acid ethyl ester
• CAS NO: 109012-23-9
• Molecular Formula: C₇H₉N₃O₄
• Molecular Weight: 199.17
• Mol File: 109012-23-9.mol

Chemical Properties

• Boiling Point: 350.7 °C at 760 mmHg
• Flash Point: 165.9 °C
• Appearance: /
• Density: 1.42 g/cm³
• Vapor Pressure: 4.33E-05mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: 2-8°C
• PKA: -2.47±0.60(Predicted)
• CAS DataBase Reference: Ethyl 1-methyl-4-nitroimidazole-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 1-methyl-4-nitroimidazole-2-carboxylate(109012-23-9)
• EPA Substance Registry System: Ethyl 1-methyl-4-nitroimidazole-2-carboxylate(109012-23-9)

Safety Data

• Hazardous Substances Data: 109012-23-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 1-methyl-4-nitroimidazole-2-carboxylate is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to inhibit the transcription of several inflammatory and oncogenic genes. This makes it a valuable component in the development of drugs targeting inflammation and cancer.
Used in Chemical Research:
In the field of chemical research, Ethyl 1-methyl-4-nitroimidazole-2-carboxylate serves as a key building block for the creation of novel molecules with potential applications in various industries. Its unique structure allows for further functionalization and modification, making it a versatile compound for research purposes.
Used in Drug Delivery Systems:
Similar to its application in the pharmaceutical industry, Ethyl 1-methyl-4-nitroimidazole-2-carboxylate can be utilized in the development of drug delivery systems. Its chemical properties may enable the design of targeted drug delivery vehicles, potentially improving the efficacy and bioavailability of therapeutic agents.

InChI:InChI=1/C7H9N3O4/c1-3-14-7(11)6-8-5(10(12)13)4-9(6)2/h4H,3H2,1-2H3

Upstream product

• 30148-21-1 ethyl 1-methyl-1H-imidazole-2-carboxylate 
• 64-17-5 ethanol 
• 120095-64-9 2,2,2-trichloro-1-(1-methyl-4-nitro-1H-imidazol-2-yl)ethan-1-one 
• 141-52-6 sodium ethanolate 
• 30148-23-3 2-trichloroacetyl-1-methylimidazole 
• 865998-46-5 4-nitro-1H-imidazole-2-carboxylic acid ethyl ester 
• 74-88-4 methyl iodide 

Downstream Products

• 128293-62-9 ethyl 4-amino-1-methylimidazole-2-carboxylate 
• 109012-24-0 1-methyl-4-nitro-1H-imidazole-2-carboxylic acid 
• 128293-64-1 4-[(tert-butoxycarbonyl)amino]-1-methylimidazole-2-carboxylic acid 
• 711022-18-3 2-{1-methyl-4-[4-(1-methyl-4-(isoquinoline-3-carboxamido)-2-pyrrolecarboxamido)-1-benzamido]-2-imidazolecarboxamido}-1,1-dimethoxyethane 
• 454646-17-4 1-methyl-4-[2-(4-nitro-phenylsulfanyl)-ethoxycarbonylamino]-1H-imidazole-2-carboxylic acid 
• 454646-16-3 1-methyl-4-[2-(4-nitro-phenylsulfanyl)-ethoxycarbonylamino]-1H-imidazole-2-carboxylic acid ethyl ester 
• 535937-79-2 1-methyl-4-[2-(4-trifluoromethyl-phenylsulfanyl)-ethoxycarbonylamino]-1H-imidazole-2-carboxylic acid 
• 535937-76-9 1-methyl-4-[2-(4-trifluoromethyl-phenylsulfanyl)ethoxycarbonylamino]-1H-imidazole-2-carboxylic Acid Ethyl Ester 
• 535937-85-0 1-methyl-4-[2-(4-trifluoromethyl-benzenesulfonyl)-ethoxycarbonylamino]-1H-imidazole-2-carboxylic acid 
• 179983-39-2 1-methyl-4-[p-bis(2-chloroethyl)aminobenzamido]-imidazole-2-carboxylic acid 
• 288625-59-2 ethyl 1-methyl-4-[p-bis(2-chloroethyl)aminobenzamido]-imidazole-2-carboxylate 
• 180258-48-4 4-(4-tert-Butoxycarbonylamino-butyrylamino)-1-methyl-1H-imidazole-2-carboxylic acid 

Relevant articles and documents

Solid phase synthesis of polyamides containing imidazole and pyrrole amino acids

The solid phase synthesis of sequence specific DNA binding polyamides containing N-methylimidazole (Im) and N-methylpyrrole (Py) amino acids is described. Two monomer building blocks, Boc-Py-OBt ester and Boc-Im acid, are prepared on a 50 g scale without column chromatography. Using commercially available Boc-β-alanine-Pam resin, cycling protocols were optimized to afford high stepwise coupling yields (>99%). Deprotection by aminolysis affords up to 100 mg quantities of polyamide. Solid phase methodology increases both the number and complexity of minor groove binding polyamides which can be synthesized and analyzed with regard to DNA binding affinity and sequence specificity. The solid phase synthesis of a representative eight-residue polyamide is reported.

Fmoc solid phase synthesis of polyamides containing pyrrole and imidazole amino acids

Matrix presented Polyamides containing N-methylimidazole (Im) and N-methylpyrrole (Py) amino acids are synthetic ligands that have an affinity and specificity for DNA comparable to those of many naturally occurring DNA binding proteins. A machine-assisted Fmoc solid phase synthesis of polyamides has been optimized to afford high stepwise coupling yields (>99%). Two monomer building blocks, Fmoc-Py acid and Fmoc-Im acid, were prepared in multigram scale. Cleavage by aminolysis followed by HPLC purification affords up to 200 mg quantities of polyamide with purities and yields greater than or equal to those reported using Boc chemistry. A broader set of reaction conditions will increase the number and complexity of minor groove binding polyamides which may be prepared and help ensure compatibility with many commercially available peptide synthesizers.

HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES

The invention relates to heterocyclylamide-substituted imidazoles and methods for the production of the same, to the use thereof for the treatment and/or prophylaxis of diseases, to the use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases, and especially to the use thereof as antiviral agents, especially against cytomegaloviruses.

SEQUENCE SELECTIVE PYRROLE AND IMIDAZOLE POLYAMIDE METALLOCOMPLEXES

The present invention relates to sequence selective compounds for targeting therapeutic or diagnostic groups to polynucleotides. More particularly, the present invention relates to sequence selective targeting of metallocomplexes, such as metallodrugs and metallodiagnostics, to polynucleotides.

Method for the synthesis of pyrrole and imidazole carboxamides on a solid support

The present invention describes a novel method for the solid phase synthesis of polyamides containing imidazole and pyrrole carboxamides. The polyamides are prepared on a solid support from aromatic carboxylic acids and aromatic amines with high stepwise coupling yields (>99%), providing milligram quantities of highly pure polyamides. The present invention also describes the synthesis of analogs of the natural products Netropsin and Distamycin A, two antiviral antibiotics. The present invention also describes a novel method for the solid phase synthesis of imidazole and pyrrole carboxamide polyamide-oligonucleotide conjugates. This methodology will greatly increase both the complexity and quantity of minor-groove binding polyamides and minor-groove binding polyamide-oligonucleotide conjugates which can be synthesized and tested.

Efficient synthesis of oligo-N-methylpyrrolecarboxamides and related compounds

1-Methyl-4-nitro-2-trichloroacetylpyrrole 5, a new precursor for the syntheses of oligo-N-methylpyrrolecarboxamide antibiotics and their analogues, was prepared with facility. The versatility of 5 was demonstrated by the syntheses of oligopeptides 16-19.

Synthesis of Novel Imidazole-Containing DNA Minor Groove Binding Oligopeptides Related to the Antiviral Antibiotic Netropsin

Analysis of the structural and stereochemical requirements for the strict DNA base sequence recognition of (AT)4 and (AT)5 respectively for the oligopeptide minor groove binding agents netropsin and distamycin leads to proposals for the rational structure